GUNS (Genomic biomarker-selected umbrella neoadjuvant study for high risk localized prostate cancer) Trail

As part of our MyPOP program, a multicentre North American clinical trial, led by Dr Gleave of the VPC, has been initiated to determine if prospective genomic sequencing of patient tumours at baseline and allocation to an appropriate therapy based on the genomic markers will result in an improved clinical response. This study will include patients with high-risk localized prostate cancer, prior to any systemic or localized treatment. Patients must have histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell differentiation. Following standard treatment with an LHRH antagonist and apalutamide, patients will be assigned one of six treatments that is determined based on the genetic profile of their tumour. The trial design is summarized below.

Image

Further details can be found here.